申请人:Synta Pharmaceuticals Corp.
公开号:EP2305642A2
公开(公告)日:2011-04-06
Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I)
2 M+ or M2+Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is -O or -S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation. Also disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt.
所公开的是双(硫代酰肼酰胺)二盐,其结构式为 (I)
2 M+ 或 M2+Y 是共价键或取代或未取代的直链烃基。R1-R4 独立地为-H、脂肪族基团、取代的脂肪族基团、芳基或取代的芳基,或 R1 和 R3 与它们所键合的碳原子和氮原子,和/或 R2 和 R4 与它们所键合的碳原子和氮原子,形成一个可选择与芳香环融合的非芳香杂环。Z 是-O 或-S。M+ 是药学上可接受的一价阳离子,M2+ 是药学上可接受的二价阳离子。还公开了包含上述双(硫肼酰胺)二盐的药物组合物。进一步公开了治疗癌症患者的方法。这些方法包括给药有效量的双(硫代酰肼酰胺)二盐的步骤。